STOCK TITAN
  1. Home
  2. Sec-filings
  3. BIIB
  4. [Form 4] BIOGEN INC. Insider Trading Activity

Biogen (NASDAQ: BIIB) development chief sells shares after RSU vesting

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Biogen Inc.’s Head of Development, Priya Singhal, reported multiple equity transactions in early February 2026. On February 6, 2026, she exercised restricted stock units into 2,217 and 4,683 shares of common stock at an exercise price of $0 per share. To cover associated obligations, 1,056 and 1,412 shares of common stock were withheld at $201.18 per share. On February 9, 2026, she sold 2,660 common shares at $199.83 per share, leaving 8,043.1428 common shares owned directly and 9,367 restricted stock units outstanding that vest in three annual installments from 2024 and 2025 grant dates.

Positive

  • None.

Negative

  • None.
Insider Singhal Priya
Role Head of Development
Sold 2,660 shs ($532K)
Type Security Shares Price Value
Sale Common Stock 2,660 $199.83 $532K
Exercise Restricted Stock Unit 2,217 $0.00 --
Exercise Restricted Stock Unit 4,683 $0.00 --
Exercise Common Stock 2,217 $0.00 --
Tax Withholding Common Stock 1,056 $201.18 $212K
Exercise Common Stock 4,683 $0.00 --
Tax Withholding Common Stock 1,412 $201.18 $284K
Holdings After Transaction: Common Stock — 8,043.143 shares (Direct); Restricted Stock Unit — 2,217 shares (Direct)
Footnotes (1)
  1. The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Singhal Priya
(Last) (First) (Middle)
225 BINNEY
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Head of Development
3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/06/2026 M 2,217 A $0 8,488.1428 D
Common Stock 02/06/2026 F 1,056 D $201.18 7,432.1428 D
Common Stock 02/06/2026 M 4,683 A $0 12,115.1428 D
Common Stock 02/06/2026 F 1,412 D $201.18 10,703.1428 D
Common Stock 02/09/2026 S 2,660 D $199.83 8,043.1428 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit $0 02/06/2026 M 2,217 (1) 02/07/2027 Common Stock 2,217 $0 2,217 D
Restricted Stock Unit $0 02/06/2026 M 4,683 (2) 02/06/2028 Common Stock 4,683 $0 9,367 D
Explanation of Responses:
1. The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024.
2. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.
/s/ Wendell Taylor, attorney-in-fact for Priya Singhal 02/10/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Biogen (BIIB) executive Priya Singhal report in February 2026?

Priya Singhal reported exercising restricted stock units into common stock, share withholding to satisfy related obligations, and an open-market sale. On February 6, 2026 she converted RSUs into shares and had shares withheld, then sold 2,660 common shares on February 9, 2026.

How many Biogen (BIIB) shares did Priya Singhal sell and at what price?

She sold 2,660 shares of Biogen common stock on February 9, 2026 at a price of $199.83 per share. This sale followed RSU conversions and tax-related share withholdings reported for February 6, 2026.

What restricted stock units did Priya Singhal convert and what remains outstanding at Biogen (BIIB)?

On February 6, 2026 she exercised 2,217 and 4,683 restricted stock units into Biogen common shares. Following these transactions, 9,367 restricted stock units remained beneficially owned directly, subject to vesting in three annual installments from February 2024 and February 2025 grants.

Why were some of Priya Singhal’s Biogen (BIIB) transactions coded F on the Form 4?

Transactions coded F reflect shares withheld to cover related obligations when RSUs are settled in stock. On February 6, 2026, 1,056 and 1,412 Biogen common shares were withheld at $201.18 per share in connection with her restricted stock unit conversions.

How many Biogen (BIIB) common shares does Priya Singhal own after these February 2026 transactions?

After the reported transactions, Priya Singhal directly beneficially owned 8,043.1428 shares of Biogen common stock. This figure is reported as of the end of the sequence of transactions that included RSU conversions, share withholdings, and a 2,660-share sale.

How do Priya Singhal’s Biogen (BIIB) restricted stock units vest over time?

One RSU grant vests in three equal annual installments starting one year after the February 7, 2024 grant date. A second grant vests in three equal yearly installments beginning on the first anniversary of the February 6, 2025 grant date, subject to continued conditions.